Paris – 8 September 2015– Euronext, the primary exchange in the Euro zone, today announced the successful listing of Stallergenes Greer (currently called Ares Allergy Holding PLC), the world’s leading allergy immunotherapy specialist. Stallergenes Greer was created by the merger of Stallergenes S.A with Greer Laboratories, Inc. The new entity is listed on the Euronext Paris regulated market in compartment A.
Ares Allergy is an international pharmaceutical company specialising in the diagnosis and treatment of allergies. It develops and markets allergy immunotherapy products and services to provide lasting treatment for allergy-related respiratory diseases. By combining the assets of two top companies in its main markets, the group is now global leader in the fast-growing allergy immunotherapy sector. Ares Allergy has entities in 29 countries and 1,434 employees. In its new form, the Stallergenes Greer group reported revenue of €312.5 million in 2014, and over 500,000 patients were treated with its products.
Fereydoun Firouz, Chairman and CEO of Ares Allergy said: “By combining the resources of Stallergenes and Greer, Ares Allergy has become the worldwide leader in allergy immunotherapies. Anchored on this strong foundation, we are developing a growth strategy to allow allergy sufferers around the globe to live normal lives. Since Stallergenes has been listed on Euronext since its market debut in 1998, we opted to list Ares Allergy in Paris as well, to maintain continuity for all of our shareholders.”
Marc Lefèvre, Euronext’s head of Listing,added: “We are delighted to welcome the new Ares Allergy international group to our Paris market following its cross-border merger. Euronext is now Europe’s leading market for life science companies, with over 90listed, and Ares Allergy’s decision to list here illustrates just how attractive our markets are for these businesses. Euronext offers a springboard for raising companies’ visibility with major international investors, and Ares Allergy will be able to make full use of the many financing and liquidity tools we offer our issuers.”
Including pharmaceutical companies